ArticlePloS one2019
Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Screening for Potential Drug-Drug Interactions in Patients Receiving Anticoagulant Therapy: A Comparison of Three Drug Interaction Databases for Consistency in Severity Rating, Evidence Classification, and Clinical Management.Medicina (Kaunas, Lithuania) · 2026Article
- Nationwide assessment of community pharmacists' practices and atorvastatin-drug interactions in Egypt.Scientific reports · 2026Article
- Comparative evaluation of artificial intelligence platforms and drug interaction screening databases using real-world patient data.Exploratory research in clinical and social pharmacy · 2025Article
- Article
- Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review.Frontiers in pharmacology · 2025Review
- Metabolic syndrome: risk factors and molecular drug targets.EXCLI journal · 2025Review
- A comparison of five different drug-drug interaction checkers for selective serotonin reuptake inhibitors.Frontiers in pharmacology · 2025Article
- Drug-Drug Interactions Involving High-Alert Medications that Lead to Interaction-Associated Symptoms in Pediatric Intensive Care Patients: A Retrospective Study.Paediatric drugs · 2024Article
- Categorical Analysis of Database Consistency in Reporting Drug-Drug Interactions for Cardiovascular Diseases.Pharmaceutics · 2024Article
- Article
- Potential drug-drug interactions of frequently prescribed medications in long COVID detected by two electronic databases.PloS one · 2023Article
- Article
- Potential Drug Interactions in Adults Living in Manaus: A Real-World Comparison of Two Databases, 2019.Turkish journal of pharmaceutical sciences · 2022Article
- Antiretroviral drug-drug interactions: A comparison of online drug interaction databases.Journal of clinical pharmacy and therapeutics · 2022Article
- Prevalence of potential drug-drug interactions with disease-specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study.Pulmonary circulation · 2022Article
- Determination of potential drug-drug interactions in prescription orders dispensed in a community pharmacy setting using MicromedexInternational journal of clinical pharmacy · 2022Observational
- Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.Frontiers in pharmacology · 2022Article
- Comparing Potential Drug-Drug Interactions in Companion Animal Medications Using Two Electronic Databases.Veterinary sciences · 2021Article
- Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.Archives of medical research · 2021Review
- Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-drug interactions (DDIs) are one of the most common drug-related problems. Recently, electronic databases have drug interaction tools to search for potential DDIs, for example, Micromedex and Drugs.com. However, Micromedex and Drugs.com have different abilities in detecting potential DDIs, and this might cause misinformation to occur between patients and health care providers. METHODS AND
findingsThe aim of this study was to compare the ability of Micromedex and Drugs.com to detect potential DDIs with metabolic syndrome medications using the drug list from the U-central database, King Chulalongkorn Memorial Hospital in April 2019. There were 90 available drugs for the treatment of the metabolic syndrome and its associated complications, but six were not found in the Micromedex and Drugs.com databases; therefore, only 84 items were used in the present study. There were 1,285 potential DDI pairs found by the two databases. Micromedex reported DDIs of 724 pairs, while, Drugs.com reported 1,122 pairs. For the severity of the potential DDI reports, the same severity occurred between the two databases of 481 pairs (37.43%) and a different severity for 804 pairs (62.57%).
conclusionDrugs.com had a higher sensitivity to detect potential DDIs by approximately 1.5-fold, but Micromedex supplied more informative documentation for the severity classification. Therefore, pharmacists should use at least two databases to evaluate potential DDIs and determine the appropriate drug regimens for physician communications and patient consultations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.